Table 3.

Clinical features of sarcoidosis patients.

	Patients (n:70)
First symptom, n(%) Lung Skin Erythema nodosum Joint Eye Peripheral LAP Neurological	35(50) 10(14,3) 6(8,6) 10(14,3) 6(8,6) 2(2,9) 1(1,4)
Tissue diagnosis, n(%)* Mediastinal LAP Peripheral LAP Skin Bone marrow Liver Lung parenchyma Other **	36(55,38) 15(23,07) 11(16,9) 4(6,15) 2(3,07) 1(1,53)
Involved organ, n(%) Pulmonary Extrapulmonary Joint Arthralgia Arthritis Skin Erythema nodosum Eye Peripheral LAP Liver/Spleen Bone marrow CNS PNS Parotid Kidney Heart Other ***	67(95,7) 58(%82.85) 45(64,3) 45(64,3) 34(48,6) 34(48,6) 19(27,1) 18(25,7) 19(27,1) 4(5,7) 4(5,7) 4(5,7) 2(2,9) 3(4,3) 4(5,7) 2(2,9)
Stage of sarcoidosis, n(%) Stage 1 Stage 2 Stage 3 Stage 4	36(51,4) 24(34,3) 6(8,6) 1(1,4)
Arthritis, n(%) Ankle Knee Foot joints Elbow Wrist Hand joints	19(27,1) 12(17,1) 6(8,6) 1(1,4) 3(4,3) 4(5,7)
Reason for treatment, n(%) Lung involvement Joint involvement Eye involvement Skin involvement Neurological involvement Liver involvement	29(41) 17(24,2) 9(12.8) 7(10) 3(4,28) 2(2,85)
Treatments, n(%) Corticosteroid Methotrexate Azathioprine Mycophenolate mofetil Cyclophosphamide Hydroxychloroquine Colchicine TNF-a inhibitor Untreated	66(94,3) 32(45,7) 12(17,1) 1(1,4) 1(1,4) 10(14,3) 14(20) 3(4,3) 3(4,3)
Mortality, n(%)	1(1,4)
Disease activity Remission Active	68(98,6) 1(1,4)

*65 patients had tissue biopsy, 10 patients had tissue biopsy from more than one organ

**1 nasal mucosa, 1 pharyngeal wall, 1 parotid, 1 peritoneum, 1 minor salivary gland

***1 nasopharynx, 1 vertebra involvement

CNS: central nervous system, PNS: peripheral nervous system, TNF-a: tumor necrosis factor alfa